Sangamo receives $13m upfront in Shire haemophilia deal
This article was originally published in Scrip
Executive Summary
Shire has signed a collaboration and licence agreement with Sangamo BioSciences to develop therapeutics for haemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein (ZFP) technology. Shire is to pay Sangamo $13 million up front followed by research, regulatory, development and commercial milestone payments, and royalties on product sales.